{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["39"],"submitter":["Perez-Martinez A"],"pubmed_abstract":["<h4>Background</h4>Effective treatments are still needed to reduce the severity of symptoms, time of hospitalization, and mortality of COVID-19. SARS-CoV-2 specific memory T-lymphocytes obtained from convalescent donors recovered can be used as passive cell immunotherapy.<h4>Methods</h4>Between September and November 2020 a phase 1, dose-escalation, single centre clinical trial was conducted to evaluate the safety and feasibility of the infusion of CD45RA<sup>-</sup> memory T cells containing SARS-CoV-2 specific T cells as adoptive cell therapy against moderate/severe cases of COVID-19. Nine participants with pneumonia and/or lymphopenia and with at least one human leukocyte antigen (HLA) match with the donor were infused. The first three subjects received the lowest dose (1 × 10<sup>5</su"],"journal":["EClinicalMedicine"],"pagination":["101086"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8361305"],"repository":["biostudies-literature"],"pubmed_title":["Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE)."],"pmcid":["PMC8361305"],"pubmed_authors":["Sanchez-Zapardiel E","Balas A","Buckley RM","Guerra-Garcia P","Moreno MA","Arribas JR","Gasior M","Mora-Rillo M","De Paz R","Vicario JL","Perez-Martinez A","Pascual-Miguel B","Queiruga-Parada J","Marcos A","Ferreras C","Garcia I","Eguizabal C","Mestre-Duran C","Carcas AJ","Montejano R","Soria B","Borobia AM","Solano C"],"additional_accession":[]},"is_claimable":false,"name":"Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE).","description":"<h4>Background</h4>Effective treatments are still needed to reduce the severity of symptoms, time of hospitalization, and mortality of COVID-19. SARS-CoV-2 specific memory T-lymphocytes obtained from convalescent donors recovered can be used as passive cell immunotherapy.<h4>Methods</h4>Between September and November 2020 a phase 1, dose-escalation, single centre clinical trial was conducted to evaluate the safety and feasibility of the infusion of CD45RA<sup>-</sup> memory T cells containing SARS-CoV-2 specific T cells as adoptive cell therapy against moderate/severe cases of COVID-19. Nine participants with pneumonia and/or lymphopenia and with at least one human leukocyte antigen (HLA) match with the donor were infused. The first three subjects received the lowest dose (1 × 10<sup>5</su","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2026-05-09T03:25:53.735Z","creation":"2022-02-11T11:20:45.721Z"},"accession":"S-EPMC8361305","cross_references":{"pubmed":["34405140"],"doi":["10.1016/j.eclinm.2021.101086"]}}